Recurrent Glioma: Clinical Trials

14 trials for Recurrent Glioma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 active not recruiting, 6 completed, 1 terminated, 1 unknown. 14 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 214Active not recruiting 6, Completed 6, Terminated 1, Unknown 1
Phase 11Completed 1

Follow Recurrent Glioma: new trials by email Literature Review of Recurrent Glioma trials Research Report on Recurrent Glioma

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
Biospecimen Collection, Erdafitinib, Magnetic Resonance Imaging - Recurrent Glioma, Recurrent WHO Grade 2 Glioma
Phase 2Active not recruitingNational Cancer Institute (NCI)302024-01-042026-10-15
Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence
Hypofractionated Stereotactic Radiotherapy, Bevacizumab - Glioma, Recurrent Glioma
Phase 2UnknownHuashan Hospital422022-10-012022-11-10
PARP Inhibition for Gliomas (PI-4G or π4g)
Niraparib - Recurrent Glioblastoma, Recurrent Astrocytoma
Phase 2TerminatedUniversity of Oklahoma152022-06-092025-05-23
Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd
Talazoparib - Recurrent Glioma, Recurrent Glioblastoma
Phase 2CompletedThe University of Hong Kong332021-01-012025-06-11
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Glioblastoma
Phase 2Active not recruitingNational Cancer Institute (NCI)892019-01-302026-11-13
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor
Phase 2Active not recruitingNational Cancer Institute (NCI)202018-11-142026-11-13
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Phase 2CompletedNational Cancer Institute (NCI)232018-08-132026-04-03
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)182017-11-282026-04-21
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)202017-11-132026-04-13
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)62017-09-142024-12-11
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Ependymoma
Phase 2Active not recruitingNational Cancer Institute (NCI)92017-08-232026-11-13
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Phase 2Active not recruitingNational Cancer Institute (NCI)13772017-07-312026-11-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Phase 2Active not recruitingNational Cancer Institute (NCI)64522015-08-172026-11-12
Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma
Bevacizumab, Minocycline, Radiation - Recurrent Glioma
Phase 1 / Phase 2CompletedUniversity of Utah222012-07-062019-08-16

Narrower conditions

Glioma (14)  ·  Ependymoma (7)  ·  Hepatoblastoma (7)  ·  Histiocytosis, Langerhans-Cell (7)  ·  Lymphoma, Non-Hodgkin (7)  ·  Medulloblastoma (7)  ·  Neuroblastoma (7)  ·  Neuroectodermal Tumors, Primitive, Peripheral (7)  ·  Osteosarcoma (7)  ·  Rhabdoid Tumor (7)  ·  Rhabdomyosarcoma (7)  ·  Sarcoma (7)  ·  Wilms Tumor (7)  ·  Central Nervous System Neoplasms (5)  ·  Sarcoma, Ewing (5)

Broader conditions

Neoplasms (14)  ·  Neoplasms by Histologic Type (14)  ·  Neoplasms, Germ Cell and Embryonal (14)  ·  Neoplasms, Glandular and Epithelial (14)  ·  Neoplasms, Nerve Tissue (14)  ·  Neoplasms, Neuroepithelial (14)  ·  Neuroectodermal Tumors (14)  ·  Female Urogenital Diseases (8)  ·  Female Urogenital Diseases and Pregnancy Complications (8)  ·  Hemic and Lymphatic Diseases (8)  ·  Immune System Diseases (8)  ·  Immunoproliferative Disorders (8)  ·  Kidney Diseases (8)  ·  Kidney Neoplasms (8)  ·  Lung Diseases (8)

Interventions

Magnetic Resonance Spectroscopy (6)  ·  Specimen Handling (6)  ·  Biopsy (4)  ·  X-Rays (4)  ·  Nuclear Medicine Department, Hospital (3)  ·  Phantoms, Imaging (3)  ·  erdafitinib (3)  ·  larotrectinib (3)  ·  olaparib (3)  ·  palbociclib (3)  ·  ulixertinib (3)  ·  Bevacizumab (2)  ·  LY3023414 (2)  ·  tazemetostat (2)  ·  2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1)

Sponsors

National Cancer Institute (NCI) (10)  ·  Huashan Hospital (1)  ·  The University of Hong Kong (1)  ·  University of Oklahoma (1)  ·  University of Utah (1)

Countries

United States (12)  ·  Puerto Rico (8)  ·  Australia (1)  ·  Canada (1)  ·  China (1)  ·  Guam (1)  ·  Hong Kong (1)

Top investigators

Adam Cohen, MD (1)  ·  Aya Helali, MD, PhD (1)  ·  Donald W Parsons (1)  ·  James Battiste, MD (1)  ·  Julia Glade-Bender (1)  ·  Katherine A Janeway (1)  ·  Keith T Flaherty (1)  ·  Kieuhoa T Vo (1)  ·  Patricia M LoRusso (1)  ·  Rajen Mody (1)  ·  Susan N Chi (1)  ·  Theodore W Laetsch (1)

Results publications

PMID 31401903, PMID 26586415, PMID 32463741, PMID 33048619, PMID 33591402, PMID 35133871, PMID 35138919, PMID 35353553, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 38815151, PMID 38935895, PMID 39298716, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40675687, PMID 40865033, PMID 41066729, PMID 41166674, PMID 42686334

NIH funding

U10CA180886 (7), U10CA180820 (1), U24CA196172 (1), UM1CA186644 (1), UM1CA186689 (1)